CP and autoimmune disease: Moreover, Mito-CP can be evaluated for its suppression of EBV reactivation, which is associated with pathologies (such as infectious mononucleosis) and autoimmune diseases (such as rheumatoid arthritis and multiple sclerosis) and translated clinically in combination with other antiviral drugs.